TY - JOUR
T1 - Natriuretic Peptides
T2 - Role in the Diagnosis and Management of Heart Failure: A Scientific Statement From the Heart Failure Association of the European Society of Cardiology, Heart Failure Society of America and Japanese Heart Failure Society
AU - Tsutsui, HIROYUKI
AU - ALBERT, NANCY M.
AU - COATS, ANDREW J.S.
AU - ANKER, STEFAN D.
AU - BAYES-GENIS, ANTONI
AU - BUTLER, JAVED
AU - CHIONCEL, OVIDIU
AU - DEFILIPPI, CHRISTOPHER R.
AU - DRAZNER, MARK H.
AU - FELKER, G. MICHAEL
AU - FILIPPATOS, GERASIMOS
AU - FIUZAT, M. O.N.A.
AU - IDE, TOMOMI
AU - JANUZZI, JAMES L.
AU - KINUGAWA, KOICHIRO
AU - KUWAHARA, KOICHIRO
AU - MATSUE, Y. U.Y.A.
AU - MENTZ, ROBERT J.
AU - METRA, MARCO
AU - PANDEY, AMBARISH
AU - ROSANO, GIUSEPPE
AU - SAITO, YOSHIHIKO
AU - SAKATA, YASUSHI
AU - SATO, NAOKI
AU - SEFEROVIC, PETAR M.
AU - TEERLINK, J. O.H.N.
AU - YAMAMOTO, KAZUHIRO
AU - YOSHIMURA, MICHIHIRO
N1 - Publisher Copyright:
© 2023 Elsevier Inc., European Society of Cardiology
PY - 2023/5
Y1 - 2023/5
N2 - Natriuretic peptides, brain (B-type) natriuretic peptide (BNP) and N-terminal prohormone of brain natriuretic peptide (NT-proBNP) are globally and most often used for the diagnosis of heart failure (HF). In addition, they can have an important complementary role in the risk stratification of its prognosis. Since the development of angiotensin receptor neprilysin inhibitors (ARNIs), the use of natriuretic peptides as therapeutic agents has grown in importance. The present document is the result of the Trilateral Cooperation Project among the Heart Failure Association of the European Society of Cardiology, the Heart Failure Society of America and the Japanese Heart Failure Society. It represents an expert consensus that aims to provide a comprehensive, up-to-date perspective on natriuretic peptides in the diagnosis and management of HF, with a focus on the following main issues: (1) history and basic research: discovery, production and cardiovascular protection; (2) diagnostic and prognostic biomarkers: acute HF, chronic HF, inclusion/endpoint in clinical trials, and natriuretic peptides-guided therapy; (3) therapeutic use: nesiritide (BNP), carperitide (ANP) and ARNIs; and (4) gaps in knowledge and future directions.
AB - Natriuretic peptides, brain (B-type) natriuretic peptide (BNP) and N-terminal prohormone of brain natriuretic peptide (NT-proBNP) are globally and most often used for the diagnosis of heart failure (HF). In addition, they can have an important complementary role in the risk stratification of its prognosis. Since the development of angiotensin receptor neprilysin inhibitors (ARNIs), the use of natriuretic peptides as therapeutic agents has grown in importance. The present document is the result of the Trilateral Cooperation Project among the Heart Failure Association of the European Society of Cardiology, the Heart Failure Society of America and the Japanese Heart Failure Society. It represents an expert consensus that aims to provide a comprehensive, up-to-date perspective on natriuretic peptides in the diagnosis and management of HF, with a focus on the following main issues: (1) history and basic research: discovery, production and cardiovascular protection; (2) diagnostic and prognostic biomarkers: acute HF, chronic HF, inclusion/endpoint in clinical trials, and natriuretic peptides-guided therapy; (3) therapeutic use: nesiritide (BNP), carperitide (ANP) and ARNIs; and (4) gaps in knowledge and future directions.
KW - Heart failure, natriuretic peptides, diagnosis
KW - therapy
UR - http://www.scopus.com/inward/record.url?scp=85154592856&partnerID=8YFLogxK
U2 - 10.1016/j.cardfail.2023.02.009
DO - 10.1016/j.cardfail.2023.02.009
M3 - 学術論文
C2 - 37117140
AN - SCOPUS:85154592856
SN - 1071-9164
VL - 29
SP - 787
EP - 804
JO - Journal of Cardiac Failure
JF - Journal of Cardiac Failure
IS - 5
ER -